Noveome Biotherapeutics

Focus: Noveome Biotherapeutics is a Pittsburgh-based biotech company founded in 2002 specializing in biologics for ophthalmology, cardiovascular, and dermatology indications. The company operates as a clinical-stage developer with a focused pipeline centered on a single lead asset.

Ophthalmology Cardiovascular Dermatology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Noveome Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Noveome Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

13 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

1X ACCS

Gingivitis

Phase 1

Clinical Trials (1)

NCT02071199Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS)

Phase 1

Help build intelligence for Noveome Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio depth in ST266 with 10+ active programs across multiple high-unmet-need indications (burns, dry eye, corneal defects, periodontal disease) suggests broad clinical validation opportunity
Established biotech with 22-year operating history provides greater organizational stability than early-stage startups, with clear Phase 2 programs advancing toward potential regulatory milestones
Rare disease and specialty therapy focus aligns with higher-margin commercialization potential and differentiated competitive positioning

Watch Out For

Zero active job openings and no disclosed hiring data signal organizational contraction, consolidation, or internal resource constraints that limit near-term career growth
Single lead molecule (ST266) platform concentration creates pipeline risk; no Phase 3 programs or marketed products means revenue inflection timing remains uncertain
Lack of published financial metrics, funding transparency, and recent news makes it difficult to assess cash runway, burn rate, and likelihood of near-term financing or M&A events

Generated by Claude from Noveome Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ST266 via Intranasal Delivery

Ocular Hypertension

Phase 1

Clinical Trials (1)

NCT03901781Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects

Phase 1

ST266

Dry Eye Syndrome

Phase 1

Clinical Trials (1)

NCT02369861Study of ST266 Eye Drops in Treating Dry Eye

Phase 1